Skip to main content

Table 1 Clinical characteristics of this subject on admission

From: Dramatic mitigation of bone pain after phosphorus replacement therapy in a subject with FGF23-related hypophosphatemic osteomalacia

WBC 5350/μL CK 38 U/L Whole PTH 25.6 pg/mL
Neu 66.6% CRP 0.08 mg/dL PTHrP ≤1.0 pmol/L
Lym 25.9% PBS 83 mg/dL 1,25(OH)2D3 38.9 pg/mL
Mon 5.1% HbA1c 5.3% 25(OH)D 7 ng/mL
Eo 2.2% LDL-chol 95 mg/dL ACTH 27.8 pg/mL
Bas 0.2% HDL-chol 41 mg/dL Cortisol 6.6 μg/dL
RBC 405 × 104/μL TG 118 mg/dL DHEA-S 74 μg/dL
Hb 12.8/μL TSH 0.66 μU/mL FGF23 275 pg/mL
Ht 37.7/μL FT4 1.05 ng/dL Osteocalcin 7.6 ng/mL
plt 18.5 × 104/μL IgG 931 mg/dL Serum NTx 22.8 nmol BCE/L
TP 6.1 g/dL IgA 141.6 mg/dL TRACP-5b 357 mU/dL
Alb 3.8 g/dL IgM 48.7 mg/dL BAP 88.2 μg/L
T-bil 0.3 mg/dL Na 141 mEq/L ucOC 1.93 ng/mL
AST 22 U/L K 3.9 mEq/L Intact PINP 96.5 μg/L
ALT 17 U/L IP 1.5 mg/dL CEA 1.5 ng/mL
γGTP 50 U/L Ca 8.1 mg/dL CA19-9 7.9 U/mL
ALP 855 U/L Corrected Ca 8.3 mg/dL CA125 8 U/mL
LDH 166 U/L Urinary Cre 21 mg/dL SLX 20.0 U/mL
ChE 295 U/L Urinary P 5.9 mg/dL AFP 2.4 ng/mL
Crn 0.37 mg/dL Urinary Ca 9.9 mg/dL SCC 1.9 ng/mL
BUN 11 mg/dL FECa 4.46% CYFRA 1.8 ng/mL
UA 4.8 mg/dL Tmp/GFR 1.40 mg/dL ProGRP 45.6 pg/mL